D. Boral Capital Reaffirms Buy Rating for Coya Therapeutics (NASDAQ:COYA)

Coya Therapeutics (NASDAQ:COYA)‘s stock had its “buy” rating reiterated by investment analysts at D. Boral Capital in a research report issued to clients and investors on Wednesday,Benzinga reports. They currently have a $15.00 target price on the stock. D. Boral Capital’s target price points to a potential upside of 168.34% from the company’s previous close.

Several other brokerages also recently issued reports on COYA. HC Wainwright reissued a “buy” rating and set a $18.00 target price on shares of Coya Therapeutics in a research note on Monday, November 11th. Chardan Capital reissued a “buy” rating and issued a $14.00 target price on shares of Coya Therapeutics in a report on Thursday, November 7th.

Coya Therapeutics Price Performance

Shares of Coya Therapeutics stock opened at $5.59 on Wednesday. Coya Therapeutics has a 1-year low of $4.75 and a 1-year high of $10.69. The company’s fifty day simple moving average is $7.04 and its 200-day simple moving average is $6.66. The stock has a market capitalization of $93.39 million, a PE ratio of -8.63 and a beta of 0.26.

Coya Therapeutics (NASDAQ:COYA) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.15. As a group, research analysts anticipate that Coya Therapeutics will post -1.15 EPS for the current year.

Insider Transactions at Coya Therapeutics

In other news, CEO Arun Swaminathan purchased 5,000 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The shares were bought at an average cost of $7.34 per share, for a total transaction of $36,700.00. Following the acquisition, the chief executive officer now owns 5,000 shares of the company’s stock, valued at approximately $36,700. This trade represents a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have bought 9,510 shares of company stock valued at $69,615 in the last ninety days. Corporate insiders own 12.00% of the company’s stock.

Institutional Trading of Coya Therapeutics

Several hedge funds have recently modified their holdings of COYA. Geode Capital Management LLC grew its stake in Coya Therapeutics by 3.3% during the 3rd quarter. Geode Capital Management LLC now owns 142,309 shares of the company’s stock worth $918,000 after buying an additional 4,485 shares during the last quarter. GHP Investment Advisors Inc. purchased a new position in Coya Therapeutics in the 3rd quarter worth $169,000. Renaissance Technologies LLC acquired a new stake in Coya Therapeutics during the 2nd quarter worth about $101,000. Finally, Gilbert & Cook Inc. purchased a new stake in Coya Therapeutics during the 2nd quarter valued at about $61,000. 39.75% of the stock is owned by hedge funds and other institutional investors.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.